dc.contributor.author | Zamudio, Roxana | |
dc.contributor.author | Hijazi, Karolin | |
dc.contributor.author | Joshi, Chaitanya | |
dc.contributor.author | Aitken, Emma | |
dc.contributor.author | Oggioni, Marco R. | |
dc.contributor.author | Gould, Ian M. | |
dc.date.accessioned | 2020-03-02T00:02:39Z | |
dc.date.available | 2020-03-02T00:02:39Z | |
dc.date.issued | 2019-06 | |
dc.identifier | 142321391 | |
dc.identifier | 5028c3d3-b910-4be3-b541-663a4df4aa0e | |
dc.identifier | 85064169470 | |
dc.identifier | 000468880600009 | |
dc.identifier.citation | Zamudio , R , Hijazi , K , Joshi , C , Aitken , E , Oggioni , M R & Gould , I M 2019 , ' Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients ' , International Journal of Antimicrobial Agents , vol. 53 , no. 6 , pp. 774-780 . https://doi.org/10.1016/j.ijantimicag.2019.02.022 | en |
dc.identifier.issn | 0924-8579 | |
dc.identifier.other | Mendeley: 71996a89-4381-39fc-a029-3d9b49edbc3e | |
dc.identifier.other | ORCID: /0000-0002-8589-2129/work/59177121 | |
dc.identifier.uri | https://hdl.handle.net/2164/13764 | |
dc.description | ACKNOWLEDGEMENTS We thank the staff of the Medical Microbiology Laboratory at Aberdeen Royal Infirmary for their dedicated support to this study. We thank the Oxford Genomics Centre at the Wellcome Centre for Human Genetics (funded by Wellcome Trust grant reference 203141/Z/16/Z) for the generation and initial processing of the sequencing data. FUNDING This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. | en |
dc.format.extent | 7 | |
dc.format.extent | 1095102 | |
dc.language.iso | eng | |
dc.relation.ispartof | International Journal of Antimicrobial Agents | en |
dc.subject | SDG 3 - Good Health and Well-being | en |
dc.subject | Pseudomonas aeruginosa | en |
dc.subject | cystic fibrosis | en |
dc.subject | ceftazidime/avibactam | en |
dc.subject | ceftolozane/tazobactam | en |
dc.subject | ampC | en |
dc.subject | AmpD | en |
dc.subject | oprD | en |
dc.subject | mutation-driven evolution | en |
dc.subject | Ceftolozane/tazobactam | en |
dc.subject | Cystic fibrosis | en |
dc.subject | Ceftazidime/avibactam | en |
dc.subject | R Medicine (General) | en |
dc.subject | Microbiology (medical) | en |
dc.subject | Infectious Diseases | en |
dc.subject | Pharmacology (medical) | en |
dc.subject | Wellcome Trust | en |
dc.subject | 203141/Z/16/Z | en |
dc.subject | Supplementary Data | en |
dc.subject.lcc | R1 | en |
dc.title | Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients | en |
dc.type | Journal article | en |
dc.contributor.institution | University of Aberdeen.Dental Education | en |
dc.contributor.institution | University of Aberdeen.Medicine, Medical Sciences & Nutrition | en |
dc.contributor.institution | University of Aberdeen.Other Applied Health Sciences | en |
dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
dc.description.status | Peer reviewed | en |
dc.identifier.doi | 10.1016/j.ijantimicag.2019.02.022 | |
dc.date.embargoedUntil | 2020-03-02 | |
dc.identifier.url | http://www.scopus.com/inward/record.url?scp=85064169470&partnerID=8YFLogxK | en |
dc.identifier.url | http://www.mendeley.com/research/phylogenetic-analysis-resistance-ceftazidimeavibactam-ceftolozanetazobactam-carbapenems-piperacillin | en |